Literature DB >> 18021089

Susceptibility genes and B-chronic lymphocytic leukaemia.

Susan L Slager1, Neil E Kay, Zachary S Fredericksen, Alice H Wang, Mark Liebow, Julie M Cunningham, Celine M Vachon, Timothy G Call, James R Cerhan.   

Abstract

Common genetic variants are thought to increase the risk of chronic lymphocytic leukaemia (CLL), and case-control studies provide an approach to detect these variants. There have been multiple candidate gene studies published to date, but relatively few disease pathway studies or large genomic association studies. We summarize the results of these previous studies, as well as present results from our recent large pathway study of 9412 single nucleotide polymorphisms from 1253 immunity and inflammation genes in a study of 126 CLL cases and 484 frequency-matched controls. Several promising genes have been identified as susceptibility genes for risk of CLL across all of these association studies. However, a number of candidate gene studies have not been replicated in follow-up studies, whereas the results from disease pathway and large genomic studies have yet to be replicated in an independent sample. The challenge of future studies of this type will be overcoming study design issues, including definition of CLL, sample size limitations and multiple testing issues.

Entities:  

Mesh:

Year:  2007        PMID: 18021089     DOI: 10.1111/j.1365-2141.2007.06872.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Genetic susceptibility variants for chronic lymphocytic leukemia.

Authors:  Susan L Slager; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Rassenti; Jose F Leis; Nicola J Camp; Neil E Kay; Celine M Vachon; Martha Glenn; J Brice Weinberg; Kari G Rabe; Julie M Cunningham; Sara J Achenbach; Curtis A Hanson; Gerald E Marti; Timothy G Call; Neil E Caporaso; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

2.  Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

Review 3.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 4.  Familial chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Susan L Slager; Neil E Caporaso
Journal:  Curr Opin Hematol       Date:  2010-07       Impact factor: 3.284

Review 5.  Monoclonal B cell lymphocytosis: clinical and population perspectives.

Authors:  Neil E Caporaso; Gerald E Marti; Ola Landgren; Elizabeth Azzato; J Brice Weinberg; Lynn Goldin; Tait Shanafelt
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 6.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

7.  Evolution of a precursor.

Authors:  Neil E Caporaso; Gerald E Marti; Robert F Vogt; Youn K Shim; Dan Middleton; Ola Landgren
Journal:  Cytometry B Clin Cytom       Date:  2010-01       Impact factor: 3.058

Review 8.  Familial chronic lymphocytic leukemia: what does it mean to me?

Authors:  Susan L Slager; Neil E Kay
Journal:  Clin Lymphoma Myeloma       Date:  2009

Review 9.  Inherited predisposition to chronic lymphocytic leukemia.

Authors:  Jennifer R Brown
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

Review 10.  Genetic susceptibility to chronic lymphocytic leukemia.

Authors:  Susan L Slager; Neil E Caporaso; Silvia de Sanjose; Lynn R Goldin
Journal:  Semin Hematol       Date:  2013-10       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.